Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diet and fasting combo shows promise for Alzheimer's patients

NCT ID NCT06898424

Disease control Sponsor: Prof. Lutfu Hanoglu, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a plant-based ketogenic diet combined with intermittent fasting (called Ketoflex 12/3) could slow the progression of early-to-mid stage Alzheimer's disease. Sixty participants followed the diet, and researchers measured changes in memory and thinking using a standard test. The goal was to see if this dietary approach could help control the disease and improve cognitive function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 50-85 years * Clinical Dementia Rating (CDR) score of 1 or2 * Diagnosis of Alzheimer's disease (AD) according to NIA-AA criteria Exclusion Criteria: * Alcohol and/or substance dependence * Diagnosis of chronic renal failure * Diagnosis of another neuropsychiatric disorder * Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer type dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction Intermittent Fasting Nerve Degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer type dementia Alzheimer'S disease (AD)

Contacts and locations

Locations

  • Istanbul Medipol Universitesi

    Istanbul, 34214, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.